-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CAL-02 in Community Acquired Pneumonia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CAL-02 in Community Acquired Pneumonia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CAL-02 in Community Acquired Pneumonia Drug Details: CAL-02 (combioxin) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Docetaxel in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Docetaxel in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Docetaxel in Non-Small Cell Lung Cancer Drug Details: docetaxel (ATI-1123)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CAL-02 in Community-Acquired Bacterial Pneumonia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CAL-02 in Community-Acquired Bacterial Pneumonia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CAL-02 in Community-Acquired Bacterial Pneumonia Drug Details: CAL-02 (combioxin) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rezafungin Acetate in Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rezafungin Acetate in Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rezafungin Acetate in Pneumocystis Pneumonia (Pneumocystosis/Pneumocystis jiroveci Pneumonia)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cisplatin + Vinblastine Sulphate) in Colon Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cisplatin + Vinblastine Sulphate) in Colon Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cisplatin + Vinblastine Sulphate) in Colon Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Belantamab Mafodotin in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belantamab Mafodotin in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Belantamab Mafodotin in Multiple Myeloma (Kahler Disease) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PF-07799933 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PF-07799933 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PF-07799933 in Solid Tumor Drug Details: PF-07799933 (ARRY-440) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zanidatamab in Metastatic Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zanidatamab in Metastatic Colorectal Cancer Drug Details: Zanidatamab is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OX-40 Agonist Mab in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OX-40 Agonist Mab in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OX-40 Agonist Mab in Solid Tumor Drug Details: Monoclonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KP-483 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KP-483 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KP-483 in Solid Tumor Drug Details: KP-483 is under development for...